MX2021006037A - Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion. - Google Patents
Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion.Info
- Publication number
- MX2021006037A MX2021006037A MX2021006037A MX2021006037A MX2021006037A MX 2021006037 A MX2021006037 A MX 2021006037A MX 2021006037 A MX2021006037 A MX 2021006037A MX 2021006037 A MX2021006037 A MX 2021006037A MX 2021006037 A MX2021006037 A MX 2021006037A
- Authority
- MX
- Mexico
- Prior art keywords
- nutritional supplements
- fast
- medicinal compounds
- plant
- based medicinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Abstract
Se describen compuestos medicinales o suplementos nutricionales de base vegetal en diversas combinaciones de portador. Los portadores pueden incluir aminoácidos grasos N-acilados, potenciadores de penetración y/o diversos otros portadores favorables. Las combinaciones de portador/composición de base vegetal pueden crear beneficios de administración.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662326490P | 2016-04-22 | 2016-04-22 | |
US201662429544P | 2016-12-02 | 2016-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006037A true MX2021006037A (es) | 2021-07-06 |
Family
ID=60117058
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012913A MX2018012913A (es) | 2016-04-22 | 2017-04-21 | Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion. |
MX2021006037A MX2021006037A (es) | 2016-04-22 | 2018-10-22 | Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012913A MX2018012913A (es) | 2016-04-22 | 2017-04-21 | Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion. |
Country Status (13)
Country | Link |
---|---|
US (3) | US10588974B2 (es) |
EP (2) | EP3445356B1 (es) |
JP (3) | JP6983868B2 (es) |
KR (1) | KR102393596B1 (es) |
CN (1) | CN109069475B (es) |
AU (3) | AU2017252575B2 (es) |
BR (1) | BR112018071518A2 (es) |
CA (1) | CA3021660A1 (es) |
CL (1) | CL2018002997A1 (es) |
CO (1) | CO2018011299A2 (es) |
IL (2) | IL262505B (es) |
MX (2) | MX2018012913A (es) |
WO (1) | WO2017185038A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102393596B1 (ko) | 2016-04-22 | 2022-05-04 | 리셉터 홀딩스, 인크. | 속효성 식물-계 의약 화합물 및 영양 보충제 |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
CN110121337A (zh) * | 2017-01-03 | 2019-08-13 | 受体控股公司 | 药用化合物和营养补充剂 |
WO2018175992A1 (en) * | 2017-03-23 | 2018-09-27 | Receptor Life Sciences | Rapid and controlled delivery of compositions with restored entourage effects |
EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
WO2019200482A1 (en) * | 2018-04-18 | 2019-10-24 | Canopy Growth Corporation | Cannabis placebo compositions, delivery vehicles and a method for colour matching/neutralization of cannabis products |
CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
UY38480A (es) * | 2018-11-19 | 2020-06-30 | Receptor Holdings Inc | Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides |
US20200215024A1 (en) * | 2019-01-08 | 2020-07-09 | Replennabis LLC | Cannabinoid formulations for treating alcohol hangover |
WO2020163866A1 (en) * | 2019-02-08 | 2020-08-13 | Schedule 1 Therapeutics, Inc. | Compositions comprising cannabinoids and methods of use thereof |
US11622956B1 (en) | 2019-06-26 | 2023-04-11 | RCR BioPharma | Compound and method for treating diseases and disorders |
EP4349182A2 (en) | 2019-08-30 | 2024-04-10 | Evie Sa | Loaded granules, their process of production and their uses |
CN111517980B (zh) * | 2020-05-14 | 2021-02-09 | 台州浦凯医药科技有限公司 | N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途 |
JP2023527238A (ja) * | 2020-05-29 | 2023-06-27 | 杭州先▲為▼▲達▼生物科技有限公司 | N-[8-(2-ヒドロキシベンゾイル)アミノ]オクタン酸カリウム結晶多形ならびにその調製方法及び使用 |
CN113735734B (zh) * | 2020-05-29 | 2023-12-08 | 杭州先为达生物科技股份有限公司 | N-[8-(2-羟基苯甲酰基)氨基]辛酸钾晶体多晶型物及其制备方法和用途 |
US11938152B2 (en) | 2020-08-06 | 2024-03-26 | Kedar N Prasad | High-dose antioxidants in cancer treatment |
WO2023287891A1 (en) * | 2021-07-13 | 2023-01-19 | Demetrix, Inc. | Compositions and methods using cannabinoid compounds for regulating gastric acid secretion to treat gastroesophageal reflux disease and related conditions |
WO2023091173A1 (en) * | 2021-11-16 | 2023-05-25 | Michael Hudnall | Methods of liver disease treatment |
CN114539091A (zh) * | 2022-03-11 | 2022-05-27 | 佛山奕安赛医药科技有限公司 | 异棕榈酰氨基酸类化合物及其制备方法和应用 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2385365A (en) | 1943-02-17 | 1945-09-25 | Wisconsin Alumni Res Found | Salicylic acid compounds for safer therapeutic use |
US3939259A (en) | 1974-05-24 | 1976-02-17 | Anthony Pescetti | Coating composition and therapeutic preparation incorporating same |
DE2537232B2 (de) | 1974-08-22 | 1976-07-01 | Spritz- und formmasse | |
US4374082A (en) | 1981-08-18 | 1983-02-15 | Richard Hochschild | Method for making a pharmaceutical and/or nutritional dosage form |
EP0273209B1 (en) | 1986-12-30 | 1992-01-15 | American Cyanamid Company | Composition of matter containing polycarbophil |
US4758597A (en) | 1987-05-15 | 1988-07-19 | University Patents, Inc. | Carenadiol and derivatives |
US4902513A (en) | 1987-07-31 | 1990-02-20 | Jean Carvais | Oral sustained release medicament |
US5965162A (en) | 1993-09-10 | 1999-10-12 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom |
US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
BR9604880A (pt) * | 1995-03-31 | 1998-05-19 | Emisphere Tech Inc | Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica |
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
AU1833600A (en) | 1998-11-24 | 2000-06-19 | Andreas Goutopoulos | Cannabimimetic lipid amides as useful medications |
JP2000256323A (ja) | 1999-01-08 | 2000-09-19 | Japan Tobacco Inc | 2−オキソキノリン化合物及びその医薬用途 |
CA2369591C (en) | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Disodium salts, monohydrate, and ethanol solvates |
US6495177B1 (en) | 1999-08-13 | 2002-12-17 | Warner Chilcott Laboratories Ireland Limited | Orally dissolvable nutritional supplement |
AU7581800A (en) | 1999-09-14 | 2001-04-17 | Smithkline Beecham Corporation | Process for making aqueous coated beadlets |
GB0007419D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
EP1231273A1 (en) | 2001-02-12 | 2002-08-14 | Plant Research International B.V. | Terpene synthase/cyclase and olefin synthase and uses thereof |
EP2292211A3 (en) | 2001-02-14 | 2014-01-01 | GW Pharma Limited | Mucoadhesive pharmaceutical formulations |
GB2377633A (en) | 2001-05-11 | 2003-01-22 | Gw Pharmaceuticals Ltd | Pharmaceutical compositions comprising the cannabinoids THC and CBD |
PT1385498E (pt) | 2001-04-18 | 2007-12-14 | Prometic Biosciences Inc | Ácidos gordos como factores de sobrevivência e activação de neutrófilos |
IL143318A0 (en) | 2001-05-23 | 2002-04-21 | Herbal Synthesis Corp | Herbal compositions for the treatment of mucosal lesions |
AU2002352974A1 (en) | 2001-11-29 | 2003-06-10 | Emisphere Technologies, Inc. | Formulations for oral administration of cromolyn sodium |
PT1492511E (pt) | 2002-04-09 | 2009-04-09 | Flamel Tech Sa | Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s) |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
GB0222077D0 (en) | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
EP1567513A2 (en) | 2002-12-04 | 2005-08-31 | Pharmos Corporation | High enantiomeric purity dexanabinol for pharmaceutical copositions |
AU2003301121A1 (en) | 2002-12-18 | 2004-07-14 | Pain Therapeutics, Inc. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
EP1694300A4 (en) | 2003-12-09 | 2009-04-29 | Pharmasset Inc | DOSAGE PROCESS FOR BETA-D-2 ', 3'-DIDEOXY-2', 3'-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY |
WO2005065661A2 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
IL162636A0 (en) | 2004-06-20 | 2005-11-20 | Yissum Res Dev Co | Resorcinol derivatives and their use for lowering blood pressure |
JP2008517901A (ja) | 2004-10-22 | 2008-05-29 | ファーモス コーポレイション | 経口で有効なカンナビノイド類似体 |
TWI360539B (en) | 2004-10-28 | 2012-03-21 | Shionogi & Co | 3-carbamoyl-2-pyridone derivatives |
GB0507167D0 (en) | 2005-04-08 | 2005-05-18 | Glaxosmithkline Consumer Healt | Composition |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
EP1893753B1 (en) | 2005-06-17 | 2015-12-23 | Firmenich Sa | Novel sesquiterpene synthases and methods of their use |
WO2008134071A1 (en) | 2007-04-26 | 2008-11-06 | Theraquest Biosciences, Inc. | Multimodal abuse resistant extended release formulations |
US9265724B2 (en) | 2005-11-07 | 2016-02-23 | Ram B. Murty | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
DK1903866T3 (en) * | 2005-11-07 | 2016-07-25 | Murty Pharmaceuticals Inc | Improved release of tetrahydrocannabinol |
AR059035A1 (es) | 2006-01-16 | 2008-03-12 | Syngenta Participations Ag | Insecticidas derivados de antranilamida |
US20070254911A1 (en) | 2006-03-27 | 2007-11-01 | Mingde Xia | Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators |
WO2008024408A2 (en) | 2006-08-22 | 2008-02-28 | Theraquest Biosciences, Inc. | Pharmaceutical formulations of cannabinoids for application to the skin and method of use |
KR20090065519A (ko) | 2006-08-30 | 2009-06-22 | 자고텍 아게 | 니솔디핀을 포함하는 방출 제어형 고형 경구 투여 제제 |
GB0624340D0 (en) | 2006-12-06 | 2007-01-17 | Nature Therapeutics Ltd | Antimicrobial composition |
EP2139333A4 (en) | 2007-03-28 | 2010-11-10 | Merck Sharp & Dohme | SUBSTITUTED PYRIDO [3,2-E] [1,2,4] TRIAZOLO [4,3-C] PYRIMIDINE DERIVATIVES AS MODULATORS OF THE CANNABINOID-1 RECEPTOR |
ES2443817T3 (es) | 2007-11-02 | 2014-02-20 | Emisphere Technologies, Inc. | Método para tratar la deficiencia de vitamina B12 |
US20090155392A1 (en) | 2007-12-17 | 2009-06-18 | Bret David Nelson | Methods and Systems for Sublingual Guarana Administration |
WO2009100245A1 (en) | 2008-02-05 | 2009-08-13 | Emisphere Technologies Inc. | Low dose hmg-coa reductase inhibitor with reduced side effects |
US20110137040A1 (en) | 2008-08-01 | 2011-06-09 | Lange Josephus H M | Synthesis of 3,4-diaryl-4,5-dihydro-(h)-pyrazole-1-carboxamidine derivatives |
US9186412B2 (en) | 2008-08-18 | 2015-11-17 | Entera Bio Ltd. | Methods and compositions for oral administration of insulin |
CN101439074B (zh) | 2008-12-11 | 2012-06-06 | 深圳海王药业有限公司 | 苍术总萜醇提取物及其制备方法和用途 |
US20100273895A1 (en) | 2009-04-28 | 2010-10-28 | Alltranz Inc. | Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same |
CA2785056A1 (en) | 2009-12-22 | 2011-07-21 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
JP2014501728A (ja) | 2010-11-25 | 2014-01-23 | エイオーピー オーファン ファーマスーティカルズ アクチエンゲゼルシャフト | ナビロンおよびランダムにメチル化されたベータシクロデキストリンを含む速崩壊組成物 |
US20130224300A1 (en) | 2011-08-26 | 2013-08-29 | Edward T. Maggio | Compositions and methods thereof for oral administration of drugs |
ES2806034T3 (es) | 2011-09-29 | 2021-02-16 | Thc Pharm Gmbh The Health Concept | Acidos carboxílicos de cannabinoide, sales de ácidos carboxílicos de cannabinoide, su preparación y aplicaciones |
EP2601947A1 (en) | 2011-12-05 | 2013-06-12 | Abo Bakr Mohammed Ali Al-Mehdar | Fixed-dose combination for treatment of helicobacter pylori associated diseases |
AU2013233930A1 (en) | 2012-03-13 | 2014-09-25 | Piramal Enterprises Limited | Herbal composition for the treatment of metabolic disorders |
PL2844243T3 (pl) | 2012-05-03 | 2020-05-18 | Echo Pharmaceuticals B.V. | Sposób przygotowania izolatu z rośliny konopi zawierającego delta-9-tetrahydrokannabinol |
EP2666461B1 (en) | 2012-05-23 | 2015-07-01 | Tergum S.L. | Terpene extract for the treatment of hair loss |
DK2897620T3 (da) | 2012-09-21 | 2020-08-17 | Intensity Therapeutics Inc | Fremgangsmåde til behandling af cancer |
US20150273069A1 (en) | 2012-10-17 | 2015-10-01 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
US10639439B2 (en) | 2013-01-30 | 2020-05-05 | Midwest Pharmaceuticals, Llc | Smokeless THC and administration method thereof |
CN105555265A (zh) | 2013-02-28 | 2016-05-04 | 全谱实验室有限公司 | 大麻素的生物合成 |
US10792318B2 (en) | 2013-03-14 | 2020-10-06 | Sc Laboratories, Inc. | Bioactive concentrates and uses thereof |
MX2015011896A (es) | 2013-03-15 | 2016-07-19 | Korea United Pharm Inc | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. |
JP6041823B2 (ja) | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
US9326967B2 (en) * | 2013-08-22 | 2016-05-03 | Stephen C. Perry | Vaporizable cannabinoid compositions |
US9532593B2 (en) * | 2013-12-26 | 2017-01-03 | John Turner | Herbal smoking blend |
WO2015118549A1 (en) | 2014-02-10 | 2015-08-13 | F&C Licorice Ltd. | Encapsulated biologically active agents |
CA2845443A1 (en) | 2014-03-04 | 2015-09-04 | Pharmascience Inc. | Orally disintegrating tablet of nabilone and method of manufacturing |
GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
WO2016022936A1 (en) * | 2014-08-07 | 2016-02-11 | Murty Pharmaceuticals, Inc. | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts |
US9375417B2 (en) * | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
AU2016225026A1 (en) | 2015-02-27 | 2017-09-07 | Canopy Growth Corporation | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
WO2016205923A1 (en) | 2015-06-25 | 2016-12-29 | Compressed Perforated Puck Technologies Inc. | Ingestible plant source pill and method |
KR102393596B1 (ko) | 2016-04-22 | 2022-05-04 | 리셉터 홀딩스, 인크. | 속효성 식물-계 의약 화합물 및 영양 보충제 |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
CN110121337A (zh) | 2017-01-03 | 2019-08-13 | 受体控股公司 | 药用化合物和营养补充剂 |
WO2018165740A1 (en) | 2017-03-16 | 2018-09-20 | CannTab Therapeutics, Limited | Modified release multi-layer tablet cannabinoid formulations |
WO2018175992A1 (en) | 2017-03-23 | 2018-09-27 | Receptor Life Sciences | Rapid and controlled delivery of compositions with restored entourage effects |
AU2018345812A1 (en) | 2017-10-05 | 2020-05-14 | Spoke Sciences, Inc. | Herbal compositions with improved bioavailability |
EA202090890A1 (ru) | 2017-10-05 | 2020-09-03 | Ресептор Холдингз, Инк. | Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия |
-
2017
- 2017-04-21 KR KR1020187033084A patent/KR102393596B1/ko active IP Right Grant
- 2017-04-21 MX MX2018012913A patent/MX2018012913A/es unknown
- 2017-04-21 CA CA3021660A patent/CA3021660A1/en active Pending
- 2017-04-21 EP EP17786760.3A patent/EP3445356B1/en active Active
- 2017-04-21 WO PCT/US2017/028953 patent/WO2017185038A1/en active Application Filing
- 2017-04-21 BR BR112018071518-2A patent/BR112018071518A2/pt not_active Application Discontinuation
- 2017-04-21 AU AU2017252575A patent/AU2017252575B2/en active Active
- 2017-04-21 US US16/094,802 patent/US10588974B2/en active Active
- 2017-04-21 JP JP2019506612A patent/JP6983868B2/ja active Active
- 2017-04-21 EP EP21175803.2A patent/EP3928776A1/en active Pending
- 2017-04-21 CN CN201780024997.6A patent/CN109069475B/zh active Active
-
2018
- 2018-10-22 CL CL2018002997A patent/CL2018002997A1/es unknown
- 2018-10-22 MX MX2021006037A patent/MX2021006037A/es unknown
- 2018-10-22 IL IL262505A patent/IL262505B/en unknown
- 2018-10-22 CO CONC2018/0011299A patent/CO2018011299A2/es unknown
-
2020
- 2020-02-28 US US16/805,356 patent/US11129897B2/en active Active
-
2021
- 2021-08-23 US US17/409,417 patent/US20230075677A1/en not_active Abandoned
- 2021-11-22 JP JP2021189167A patent/JP7284241B2/ja active Active
-
2022
- 2022-01-24 IL IL290084A patent/IL290084A/en unknown
- 2022-02-16 AU AU2022201021A patent/AU2022201021B2/en active Active
-
2023
- 2023-05-17 JP JP2023081364A patent/JP2023103393A/ja active Pending
-
2024
- 2024-02-06 AU AU2024200704A patent/AU2024200704A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006037A (es) | Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion. | |
MX2019006439A (es) | Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion. | |
MX2019007968A (es) | Compuestos medicinales y suplementos nutricionales. | |
MX2020003330A (es) | Composiciones de hierbas con mejor biodisponibilidad. | |
MX2019011219A (es) | Administracion rapida y controlada de composiciones con efectos sequito restaurados. | |
CL2020000909A1 (es) | Formulaciones cannabinoides sintéticas y basadas en plantas de rapido inicio y de acción prolongada. | |
SG10201803042PA (en) | Anti-tim-3 antibodies | |
MX2015012379A (es) | Novedosas cepas de lactobacillus y los usos de las mismas. | |
MX2019006820A (es) | Composiciones nutricionales que contienen butirato y uso de las mismas. | |
MX2019007664A (es) | Sustituto de crema que comprende lipidos vegetales y alulosa. | |
PH12015500049B1 (en) | Novel protein material | |
PH12016501947A1 (en) | Gender specific synthetic nutritional compositions and nutritional systems comprising them | |
GB2569073A (en) | Animal feed supplement | |
PH12018500165A1 (en) | Gender specific synthetic nutritional compositions and nutritional systems comprising them | |
BR112018001719A2 (pt) | composição farmacêutica com micela polimérica, e, método para preparação de uma composição farmacêutica com micela polimérica. | |
MX2018001924A (es) | Composiciones nutritivas sinteticas adaptadas para infantes de edades especificas, y sistemas nutritivos que las comprenden. | |
UA92914U (uk) | Антиоксидантний та імуномодулюючий препарат "селцивіт" | |
PH12018500168A1 (en) | Gender specific synthetic nutritional compositions and nutritional systems comprising them | |
PH12016501921A1 (en) | Gender specific synthetic nutritional compositions and nutritional systems comprising them | |
PH12016501919A1 (en) | Gender specific synthetic nutritional compositions and nutritional systems comprising them | |
PH12016501918B1 (en) | Gender specific synthetic nutritional compositions and nutritional systems comprising them | |
JO3545B1 (ar) | تركيبات الناقل-الجسم المضاد وطرق صناعتها واستخدامها | |
UA93017U (uk) | Препарат "нановулін-врх" |